Pulmonary Drug Delivery Devices Market Analysis by Product (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers, and Accessories); by Application (Asthma, Cystic Fibrosis, COPD, Allergic Rhinitis, and Others); and by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and E-Commerce) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035
Buy Now Report ID: 4410 | Published Date: Feb 24, 2023
The global pulmonary drug delivery devices market is estimated to garner a revenue of ~ USD 105 Billion by the end of 2035 by growing at a CAGR of ~7% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of ~ USD 53 Billion in the year 2022. The growth of the market can be attributed to the surge in cases of asthma worldwide, coupled with increasing instances of pulmonary disorders, and growing funding from government and private organizations for better therapy management across the globe. People are now becoming more aware of these diseases and disorders, which is further expected to fuel the market over the forecast period. According to the World Health Organization, an estimated 262 million people suffered from asthma around the world in 2019 and it caused 455 000 deaths.
Global pulmonary drug delivery devices market trends such as, technological advancements in the pharmaceutical industry, increasing consumption of tobacco and smoking, backed by exposure to air pollution, along with development in drug delivery systems owing to growing health care spending are anticipated to fuel market growth during the forecast period. For instance, in February 2022, AptarGroup, Inc. launched HeroTracker Sense, a smart connected respiratory health device, that transforms a standard metered dose inhaler (pMDI) into a digital respiratory health tool. Hence, all these factors are anticipated to boost the market’s growth over the forecast period.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~7% |
|
Base Year Market Size (2022) |
~ USD 53 Billion |
|
Forecast Year Market Size (2035) |
~ USD 105 Billion |
|
Regional Scope |
|
Growth Drivers
Rising Prevalence of Chronic Respiratory Diseases as Air Pollution is Increasing - For instance, in 2019 chronic respiratory diseases accounted for more than 260,400 deaths in men and nearly 250,700 deaths in women in the United States. Chronic respiratory diseases such as obstructive pulmonary disease (COPD) and asthma are commonly treated with pulmonary devices that deliver medication to the respiratory tract, such as inhalers. These medications are used to prevent exacerbations of chronic conditions and to treat them. Thus, the rising prevalence of respiratory diseases is anticipated to propel the demand for pulmonary drug delivery devices during the forecast period.
Increase in the Number of Hospitals and Diagnostic Centers with Growing Awareness of People about Early Diagnosis - In the year 2021-22, Foreign Direct Investment (FDI) fund infusion into hospitals and diagnostic centers in India increased by 37% to USD 690 million.
Continuous Rise in COVID – 19 Cases Worldwide that Affected the Lungs of the People - For instance, the United States averaged nearly 30,000 new cases of COVID-19 every day in April 2022, 2% more than in previous weeks.
Increasing Air Pollutants Owing to Rising Industrialization and Urbanization - World Health Organization (WHO) statistics show that in 2018, 9 out of 10 people worldwide inhaled polluted air. There are about 7 million deaths each year from chronic obstructive pulmonary diseases caused by exposure to fine particles in polluted air across the globe.
Rise in Exports of Medical Appliances with Increasing Improvement and Advancements in Healthcare Sector - According to the statistics by the International Trade Center (Trademap), the global value of exports of medical appliances in the year 2021 was recorded to be USD 14,170,931 thousand, which was an increase from USD 12,754,842 thousand in the previous year.
The global pulmonary drug delivery devices market is segmented and analyzed for demand and supply by application into asthma, cystic fibrosis, COPD, allergic rhinitis, and others. Out of these segments, the COPD segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the higher prevalence and severity of this disease, backed by the fact that the treatment for COPD is subsidized by government policies and non-governmental organizations that are increasingly providing COPD treatment worldwide. Chronic obstructive pulmonary disease (COPD) can be life-threatening that requires immediate medical attention. For instance, COPD prevalence worldwide was 10% in 2019, accounting for 390 million cases among people over 40 years. Therefore, these factors are anticipated to drive segment growth during the forecast period.
The global pulmonary drug delivery devices market is also segmented and analyzed for demand and supply by product into metered dose inhalers, dry powder inhalers, nebulizers, and accessories. Amongst these segments, the nebulizers segment is expected to garner a significant share. Nebulizers are highly used for the treatment of asthma and other respiratory diseases. Nebulizers come in two types, ultrasonic and jet nebulizers. Jet nebulizers can compress air and oxygen passing by narrow orifice. Additionally, nebulizers are the traditional method to cure respiratory diseases, hence, people are more inclined to use nebulizers over other methods. Furthermore, high export and import volumes of nebulizers across the globe are also expected to propel the growth of the segment over the forecast period.
Our in-depth analysis of the global pulmonary drug delivery devices market includes the following segments:
|
By Product |
|
|
By Application |
|
|
By Distribution Channel |
|
The North America pulmonary drug delivery devices market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the increasing prevalence of lung diseases such as COPD, chronic bronchitis, and asthma in the region owing to heavy consumption of tobacco, cigarettes, exposure to air pollutants, genetic factors, and others. It was observed that in 2018, there were 8.9 million adults in the United States who experienced chronic bronchitis, or 3.5% of those over the age of 18 years. A surge in the air pollution and exposure to air pollutants in the region that results in a higher number of respiratory diseases in the population is estimated to expand the market’s size during the forecast period. As of 2021, nearly 65 million tons of pollution were estimated to be mixed in the atmosphere in the USA. Additionally, more than 62% of the Americans were noticed to be living in high air polluted areas at unhealthy levels making people sick. Furthermore, increasing healthcare spending, rising disposable income, the presence of major key players, changes in lifestyle, and growing demand for COPD therapeutics are factors anticipated to fuel the pulmonary drug delivery devices market growth in the region during the forecast period.
Novartis AG reported that a new treatment option for Japanese patients was approved by the Ministry of Health, Labour, and Welfare (MHLW). NSCLC with METex14 mutations can be treated with TabrectaTM (capmatinib, formerly INC280), an oral MET inhibitor. Tabrecta became the first-line approved treatment type for patients living with lung cancer advanced non-small cell lung cancer.
Lupin Limited launched Adhero, a smart inhaler tracking device designed to support the treatment of COPD patients and respiratory diseases. Adhero also provide therapy and assistance to the people living with chronic respiratory diseases. Additionally, Adhero is getting fame owing to the fact that inhalers are most convenient treatment methods for chronic respiratory diseases.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Rising prevalence of chronic respiratory diseases as air pollution is increasing are the major factors driving the market growth.
Ans: The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2023 – 2035.
Ans: Side effects related to long term use of the product are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are Lupin Limited, Briggs Healthcare, Inc., Boehringer Ingelheim International GmbH, Koninklijke Philips N.V., Merck & Co., Inc., 3M Company, AstraZeneca PLC, GSK plc, GF Health Products, Inc., and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by product, application, distribution channel, and by region.
Ans: The COPD segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
